Introduction Programmed cell death-1 (PD-1) is an immune checkpoint receptor that inhibits
T cell activation upon interaction with its ligands PD-L1 or PD-L2. Increased PD-L1 …

Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint
pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may …

3016 Background: The immune checkpoint receptor programmed death-1 (PD-1) negatively
regulates T-cell activation. In a phase I study, nivolumab, a PD-1 receptor blocking antibody …

Introduction: Nivolumab (nivo) is a fully human IgG4 monoclonal antibody (mAb) targeting
programmed death receptor-1 (PD-1). Nivo has demonstrated clinical activity and an …

Targeted immunotherapy has become the most promising approach for tumor patients.
Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, can …

3002^ Background: Blockade of programmed death-1 (PD-1), a co-inhibitory receptor
expressed by activated T cells, can overcome immune resistance and mediate tumor …

Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and
can restore anticancer immune responses by abrogating PD-1 pathway-mediated T-cell …

Abstract The programmed death-1 (PD-1) receptor serves as an immunologic checkpoint,
limiting bystander tissue damage and preventing the development of autoimmunity during …

8024 Background: The fully human IgG4 programmed death-1 (PD-1) immune checkpoint
inhibitor antibody nivolumab has demonstrated durable responses and tolerability in …

Background Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are
frequently expressed in T-cell lymphomas. This provides a rationale for exploration of …